Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia

被引：0
|
作者：
Bergenstal, R. M. [1 ]
Buse, J. B. [2 ]
Glass, L. C. [3 ]
Heilmann, C. R. [3 ]
Lewis, M. S. [3 ]
Kwan, A. Y. M. [4 ]
Hoogwerf, B. J. [4 ]
Rosenstock, J. [5 ]
机构：
[1] Int Diabet Ctr, Minneapolis, MN USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Lilly USA LLC, Indianapolis, IN USA
[5] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
73
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [1] Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
    Rosenstock, Julio
    Shenouda, Sylvia K.
    Bergenstal, Richard M.
    Buse, John B.
    Glass, Leonard C.
    Heilmann, Cory R.
    Kwan, Anita Y. M.
    MacConell, Leigh A.
    Hoogwerf, Byron James
    DIABETES CARE, 2012, 35 (05) : 955 - 958
  • [2] Exenatide achieved equivalent glycaemic control to insulin glargine, with weight reduction and less nocturnal hypoglycaemia, in metformin and sulfonylurea-treated type 2 diabetes
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    DIABETOLOGIA, 2005, 48 : A3 - A3
  • [3] Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
    Brodows, Robert G.
    Qu, Yongming
    Johns, Don
    Kim, Dennis
    Holcombe, John H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1395 - 1397
  • [4] Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin
    Dailey, G. E.
    Gao, L.
    Aurand, L.
    Garg, S. K.
    DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1085 - 1092
  • [5] Exenatide reduced body weight compared to insulin glargine in metformin and sulfonylurea-treated patients with type 2 diabetes
    Brodows, R
    Kim, D
    Burger, J
    Mihm, M
    Johns, D
    OBESITY RESEARCH, 2005, 13 : A132 - A132
  • [6] Dynamics of Weight Change and Glycemic Control in Patients with Type 2 Diabetes Treated with Exenatide or Insulin
    Paul, Sanjoy K.
    Best, Jennie H.
    Naughton, Margaret
    Maggs, David
    DIABETES, 2010, 59 : A181 - A181
  • [7] Duration of diabetes and hypoglycaemia rates in type 2 diabetes patients treated with insulin glargine vs NPH insulin
    Dailey, G.
    Aurand, L.
    Garg, S.
    DIABETOLOGIA, 2011, 54 : S262 - S262
  • [8] Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide
    Pujante Alarcon, Pedro
    Hellin Gil, Maria Dolores
    Miguel Roman, Luis
    Ferrer Gomez, Mercedes
    Garcia Zafra, Maria Victoria
    Tebar Masso, Javier
    MEDICINA CLINICA, 2012, 139 (13): : 572 - 578
  • [9] Once-Weekly Exenatide Used for 6 Months Provided Both Improved Glycemic Control and Weight Loss Compared to Sitagliptin, Pioglitazone, or Insulin Glargine in Metformin-Treated Patients with Type 2 Diabetes
    Horton, Edward
    Taylor, Kristin
    Porter, T. K. Booker
    Han, Jenny
    Wilhelm, Ken
    Harris, Carmen
    DIABETES, 2010, 59 : A163 - A163
  • [10] Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine
    Secnik, K
    Hayes, C
    Matza, L
    Kim, S
    Oglesby, A
    Yurgin, N
    Brodows, R
    Malley, K
    VALUE IN HEALTH, 2005, 8 (06) : A155 - A156
12345